急性基底动脉闭塞血管内治疗试验
该多中心前瞻性随机对照试验在中国36个中心纳入340例基底动脉闭塞患者,按2:1随机分配至血管内取栓组(226例)或最佳药物治疗组(114例),均在估计闭塞后12小时内。主要终点90天改良Rankin量表0-3分(良好功能状态)取栓组为46%(104例),对照组为23%(26例),调整率比2.06(95%CI 1.46-2.91,P<0.001)。症状性颅内出血取栓组5%(12例)而对照组0例,90天死亡率取栓组37% vs 对照组55%(调整风险比0.66,95%CI 0.52-0.82),操作并发症发生率14%。结论认为取栓可改善功能结局,但伴随操作并发症和脑出血风险。
要点
- 基底动脉闭塞12小时内取栓组90天良好功能(mRS 0-3分)46%(104/226)vs 对照组23%(26/114),调整率比2.06(95%CI 1.46-2.91,P<0.001)。
- 取栓组90天死亡率37% vs 对照组55%,调整风险比0.66(95%CI 0.52-0.82)。
- 取栓组症状性颅内出血(24-72小时)5%(12例),对照组0例;操作并发症14%,其中1例因动脉穿孔死亡。
- 两组静脉溶栓使用率相近:取栓组31%,对照组34%。
适用人群与场景
- 中国36个中心、基底动脉闭塞、估计闭塞后12小时内的患者,共340例纳入意向性治疗分析(取栓组226例,对照组114例)。
- 两组分别有31%(取栓组)和34%(对照组)接受了静脉溶栓。
诊断标准与关键阈值
- 基底动脉闭塞,随机化在估计闭塞时间12小时内进行。
处置流程与药物剂量
- 取栓组接受血管内取栓,对照组接受最佳药物治疗(对照)。
- 取栓组中31%的患者接受了静脉溶栓,对照组中34%接受了静脉溶栓。
红旗征与不能漏的情况
- 取栓组症状性颅内出血发生在24-72小时,发生率5%(12例)。
- 取栓组操作并发症发生率14%,包括1例因动脉穿孔死亡。
研究设计与关键结果
- 多中心、前瞻性、随机对照试验,36个中心,340例基底动脉闭塞患者(取栓组226例 vs 对照组114例),按2:1随机分配。
- 主要终点:90天改良Rankin量表0-3分(良好功能状态)取栓组46%(104例)vs 对照组23%(26例),调整率比2.06(95%CI 1.46-2.91,P<0.001)。
- 次要终点:改良Rankin量表0-2分、改良Rankin量表各分类分布及生活质量,结果总体与主要终点方向一致。
- 安全性终点:症状性颅内出血(24-72小时)取栓组5%(12例)vs 对照组0例;90天死亡率取栓组37% vs 对照组55%(调整风险比0.66,95%CI 0.52-0.82);操作并发症取栓组14%,包括1例因动脉穿孔死亡。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、随机对照试验(ATTENTION,NCT04751708)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在约三分之一接受静脉溶栓的中国基底动脉闭塞患者中,卒中发作12小时内血管内取栓较最佳药物治疗可带来更好的90天功能结局,但与操作并发症和脑出血相关。
- 取栓组症状性颅内出血发生率为5%,对照组为0,操作并发症发生率为14%,包括1例因动脉穿孔死亡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Data from trials investigating the effects and risks of endovascular thrombectomy for the treatment of stroke due to basilar-artery occlusion are limited.
METHODS: We conducted a multicenter, prospective, randomized, controlled trial of endovascular thrombectomy for basilar-artery occlusion at 36 centers in China. Patients were assigned, in a 2:1 ratio, within 12 hours after the estimated time of basilar-artery occlusion to receive endovascular thrombectomy or best medical care (control). The primary outcome was good functional status, defined as a score of 0 to 3 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]), at 90 days. Secondary outcomes included a modified Rankin scale score of 0 to 2, distribution across the modified Rankin scale score categories, and quality of life. Safety outcomes included symptomatic intracranial hemorrhage at 24 to 72 hours, 90-day mortality, and procedural complications.
RESULTS: Of the 507 patients who underwent screening, 340 were in the intention-to-treat population, with 226 assigned to the thrombectomy group and 114 to the control group. Intravenous thrombolysis was used in 31% of the patients in the thrombectomy group and in 34% of those in the control group. Good functional status at 90 days occurred in 104 patients (46%) in the thrombectomy group and in 26 (23%) in the control group (adjusted rate ratio, 2.06; 95% confidence interval [CI], 1.46 to 2.91, P<0.001). Symptomatic intracranial hemorrhage occurred in 12 patients (5%) in the thrombectomy group and in none in the control group. Results for the secondary clinical and imaging outcomes were generally in the same direction as those for the primary outcome. Mortality at 90 days was 37% in the thrombectomy group and 55% in the control group (adjusted risk ratio, 0.66; 95% CI, 0.52 to 0.82). Procedural complications occurred in 14% of the patients in the thrombectomy group, including one death due to arterial perforation.
CONCLUSIONS: In a trial involving Chinese patients with basilar-artery occlusion, approximately one third of whom received intravenous thrombolysis, endovascular thrombectomy within 12 hours after stroke onset led to better functional outcomes at 90 days than best medical care but was associated with procedural complications and intracerebral hemorrhage. (Funded by the Program for Innovative Research Team of the First Affiliated Hospital of USTC and others; ATTENTION ClinicalTrials.gov number, NCT04751708.).
参考来源
- Tao C, Nogueira RG, Zhu Y, et al. Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion. N Engl J Med. 2022. PMID: 36239644. doi:10.1056/NEJMoa2206317
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。